These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 39118222)
1. Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme. Yale JF; Major-Pedersen A; Catarig AM; Jain R; Menzen M; Holmes P Diabetes Obes Metab; 2024 Oct; 26(10):4429-4440. PubMed ID: 39118222 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Kaku K; Yamada Y; Watada H; Abiko A; Nishida T; Zacho J; Kiyosue A Diabetes Obes Metab; 2018 May; 20(5):1202-1212. PubMed ID: 29322610 [TBL] [Abstract][Full Text] [Related]
3. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170 [TBL] [Abstract][Full Text] [Related]
4. Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study. Wolffenbuttel BHR; Brugts MP; Catarig AM; Clark A; Kok M; Lieverse AG; van Soest J Adv Ther; 2023 Mar; 40(3):920-933. PubMed ID: 36542260 [TBL] [Abstract][Full Text] [Related]
5. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100 [TBL] [Abstract][Full Text] [Related]
6. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study. Rajamand Ekberg N; Bodholdt U; Catarig AM; Catrina SB; Grau K; Holmberg CN; Klanger B; Knudsen ST Prim Care Diabetes; 2021 Oct; 15(5):871-878. PubMed ID: 34183269 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Capehorn MS; Catarig AM; Furberg JK; Janez A; Price HC; Tadayon S; Vergès B; Marre M Diabetes Metab; 2020 Apr; 46(2):100-109. PubMed ID: 31539622 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867 [TBL] [Abstract][Full Text] [Related]
11. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL; Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288 [TBL] [Abstract][Full Text] [Related]
12. Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study). Caballero Mateos I; García de Lucas MD; Doulatram-Gamgaram VK; Moreno-Moreno P; Jimenez-Millan AI; Botana-López M; Merino-Torres JF; Soto-Gónzalez A; Fernández-García JC; Morales-Portillo C Nutrients; 2024 Aug; 16(15):. PubMed ID: 39125424 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Seino Y; Terauchi Y; Osonoi T; Yabe D; Abe N; Nishida T; Zacho J; Kaneko S Diabetes Obes Metab; 2018 Feb; 20(2):378-388. PubMed ID: 28786547 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654 [TBL] [Abstract][Full Text] [Related]
15. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study. Holmes P; Bell HE; Bozkurt K; Catarig AM; Clark A; Machell A; Sathyapalan T Diabetes Ther; 2021 Nov; 12(11):2891-2905. PubMed ID: 34562237 [TBL] [Abstract][Full Text] [Related]
16. Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. DeVries JH; Desouza C; Bellary S; Unger J; Hansen OKH; Zacho J; Woo V Diabetes Obes Metab; 2018 Oct; 20(10):2426-2434. PubMed ID: 29862621 [TBL] [Abstract][Full Text] [Related]
17. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. Johansen P; Sandberg A; Capehorn M Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148 [TBL] [Abstract][Full Text] [Related]
18. Semaglutide once-weekly: improved efficacy with a new safety warning. Coon SA; Crannage EF; Kerwin LC; Guyton JE Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182 [TBL] [Abstract][Full Text] [Related]
19. Safety of Semaglutide. Smits MM; Van Raalte DH Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810 [TBL] [Abstract][Full Text] [Related]
20. Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study. Mohammedi K; Belhatem N; Berentzen TL; Catarig AM; Potier L Diabetes Obes Metab; 2023 Jul; 25(7):1855-1864. PubMed ID: 36869853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]